Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Towards positive net outcomes for biodiversity, and developing safeguards to accompany headline biodiversity indicators.

npj biodiversity·2025

Same author

Sex differences in blood pressure responses of Pekin ducks to sound stimuli and conspecific vocalizations.

Poultry science·2024

Same author

Patient and public involvement and engagement (PPIE) in research: The Golden Thread.

Nursing in critical care·2024

Same author

Nature-positive goals for an organization's food consumption.

Nature food·2023

Same author

Development of clinical competence - a longitudinal survey of nurse practitioner students.

BMC nursing·2021

Same author

An 8-year Analysis of Magnesium Status in Elite International Track & Field Athletes.

Journal of the American College of Nutrition·2019

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Adjuvant systemic therapy for operable breast cancer.

S Narayanan¹, I Taylor

¹Department of Surgery, Royal Free and University College Medical School, Charles Bell House, London, UK.

The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland

|April 25, 2007

Summary

Systemic adjuvant therapy, including chemotherapy and targeted treatments like trastuzumab, is crucial for reducing breast cancer recurrence and mortality after surgery. Newer drugs offer improved outcomes for operable breast cancer patients.

More Related Videos

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jul 15, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Area of Science:

Oncology
Medical Therapeutics

Background:

Breast cancer is a leading cause of cancer death in women in England and Wales.
Systemic adjuvant therapy is vital for reducing recurrence and mortality in early and advanced breast cancer.

Purpose of the Study:

To review recent evidence on appropriate adjuvant systemic therapy following surgery for operable breast cancer.

Main Methods:

Review of recent evidence on adjuvant systemic therapy for operable breast cancer.
Focus on chemotherapy, hormonal therapy (aromatase inhibitors), and monoclonal antibodies (trastuzumab).

Main Results:

Chemotherapy and hormonal therapy have evolved significantly with new drugs like taxol and aromatase inhibitors.
Monoclonal antibodies, such as trastuzumab, are increasingly used in adjuvant settings.

Conclusions:

Adjuvant systemic therapy plays a critical role in improving outcomes for operable breast cancer.
Recent advancements in chemotherapy, hormonal therapy, and targeted therapies offer improved treatment options.